ORIGINAL RESEARCH article
Front. Med.
Sec. Precision Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1672369
This article is part of the Research TopicDeep Learning in Healthcare: Revolutionizing Diagnostics and Clinical PracticeView all 4 articles
Neoadjuvant chemotherapy impacts axillary lymph node positivity in early breast cancer (cT1-2N0M0) with negative axillary lymph nodes at diagnosis
Provisionally accepted
- 1Department of Breast Surgery ,The First Hospital of Jilin University, Changchun, China
- 2Division of Clinical Epidemiology, The First Hospital of Jilin University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Purpose: This study compared the role of neoadjuvant chemotherapy (NAC) followed by surgery vs. upfront surgery for avoiding axillary lymph node dissection (ALND) in patients with cT1-2N0M0 breast cancer and clinically negative axillary lymph nodes (LNs) at diagnosis. Patients and Methods: Medical records of a sample of 1,695 patients with a primary diagnosis of axillary LN-negative early-stage breast cancer who underwent surgical treatment for breast cancer at the First Bethune Hospital of Jilin University between June 2019 and December 2022 were retrospectively reviewed. The positive rate of sentinel lymph nodes (PRSLN) and the positive rate of total axillary lymph nodes (PRTLN) were compared between patients who received 4-8 cycles of NAC followed by surgery (n=135) and patients who underwent upfront surgery (n=1,560). Results: 15 patients who received NAC followed by surgery and 79 patients who underwent upfront surgery had positive SLNs. Four patients who received NAC followed by surgery and 1 patient who underwent upfront surgery had other positive LNs. Overall, NAC followed by surgery significantly lowered PRSLN and PRTLN compared to upfront surgery in patients with cT1-2N0M0 breast cancer. In subgroup analyses, PRSLN and PRTLN were significantly lower for NAC followed by surgery compared to upfront surgery in patients aged 40–60 years, with cT2 stage disease, and HER2+ breast cancer. At a median follow-up of 23.15 months, invasive disease-free survival was similar for all patients. Conclusion: NAC may reduce the rate of axillary LN positivity and the likelihood of ALND in patients aged 40-60 years with cT2N0M0 HER2+ breast cancer and clinically negative axillary LNs at diagnosis.
Keywords: breast cancer, Neoadjuvant chemotherapy, Sentinel Lymph Node Biopsy, Axillary lymph node dissection, Invasive disease-free survival
Received: 24 Jul 2025; Accepted: 25 Sep 2025.
Copyright: © 2025 Ma, Wang, Zhimin, Jia, Dong and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaozhen Wang, wxzhen@jlu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.